Stockscreener 앱 받기
48.28
0.90%
0.43
시간 외 거래:
48.29
0.010
+0.02%
전일 마감가:
$47.85
열려 있는:
$47.87
하루 거래량:
20.78M
Relative Volume:
1.45
시가총액:
$98.25B
수익:
$47.64B
순이익/손실:
$5.42B
주가수익비율:
18.08
EPS:
2.67
순현금흐름:
$13.09B
1주 성능:
+3.05%
1개월 성능:
-1.91%
6개월 성능:
-18.47%
1년 성능:
+19.95%
1일 변동 폭
$47.30
$48.35
1주일 범위
$46.10
$48.35
52주 변동 폭
$39.35
$63.33
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
48.28 | 95.34B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
737.67 | 640.72B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.21 | 367.98B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.11 | 323.71B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.76 | 222.69B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.50 | 299.26B | 43.59B | 15.04B | 10.74B | 3.3766 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
BMO maintains Bristol-Myers Squibb stock at Market Perform By Investing.com - Investing.com India
BMO maintains Bristol-Myers Squibb stock at Market Perform - Investing.com
Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech - Endpoints News
Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications - TradingView
EC approval for BMS’ subcutaneous Opdivo - The Pharma Letter
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock? - Yahoo Finance
EC approves BMS’ nivolumab SC formulation for solid tumours - Yahoo Finance
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
Bristol Myers Squibb (BMY) Upgraded to Buy Amid Improved Dividen - GuruFocus
Bristol Myers Squibb bags European Commission nod for Subcutaneous formulation of Opdivo across multiple... - Medical Dialogues
Bristol-Myers Squibb at Bernstein Conference: Strategic Growth and Innovation - Investing.com
BMS says subcutaneous version of Opdivo gets EU nod - FirstWord Pharma
Bristol Myers Squibb (BMY) Upgraded to Buy Amid Improved Dividend Prospects - GuruFocus
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications - BioSpace
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire
BMY Gains European Approval for New Opdivo Formulation | BMY Stock News - GuruFocus
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - marketscreener.com
Bristol Myers: EU green light for Opdivo subcutaneous injection - marketscreener.com
Bristol Myers (BMY) Gains European Approval for New Opdivo Formulation | BMY Stock News - GuruFocus
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications | BMY Stock News - GuruFocus
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Yahoo Finance
Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar (NYSE:BMY) - Seeking Alpha
Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5% (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb’s SWOT analysis: stock faces challenges amid promising pipeline - Investing.com
Deutsche Bank Accelerates Digital Transformation with IBM's Software Portfolio - The Globe and Mail
Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Showcases Breakthrough Oncology Data at ASCO 2025 Meeting - simplywall.st
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline - Yahoo Finance
Celgene Appeals Pennsylvania Tax After Bristol-Myers Acquisition - news.bloombergtax.com
Areas of interest - Bristol Myers Squibb
Bristol Myers, Novartis Take Drug Rebate Lawsuits to DC Circuit - Bloomberg Law News
Tubulis achieves key milestone in BMS deal - The Pharma Letter
Bristol Myers Squibb patents new BCL-6 degradation inducers - BioWorld MedTech
Here's How You Can Earn $100 In Passive Income By Investing In Bristol-Myers Squibb Stock - Yahoo Finance
Bristol Myers Squibb patents new USP1 inhibitors - BioWorld MedTech
Bristol Myers Promises $40 Billion US Investment Over Five Years - MSN
Bristol Myers Squibb (BMY) Gains EU Nod for Opdivo in Lung Cance - GuruFocus
Bristol Myers Squibb (BMY) Gains EU Nod for Opdivo in Lung Cancer Treatment - GuruFocus
Bristol Myers (BMY) Faces Market Movement Amid Medicare Part B & D Draft Guidance | BMY Stock News - GuruFocus
Bristol-Myers Curbs Investor $6.4 Billion Payout Suit on Appeal - Bloomberg Law News
Jim Cramer On Bristol-Myers Squibb: “Waiting For It To Bottom” - Insider Monkey
BMY Gains EU Approval for Expanded Use of Opdivo in Lung Cancer Treatment | BMY Stock News - GuruFocus
Reclaiming our time: Eightfold’s founder on the promise of agentic AI - HR Executive
BMY Secures EC Approval for Opdivo Regimen in Lung Cancer Treatm - GuruFocus
Jim Cramer On Bristol-Myers Squibb: "Waiting For It To Bottom" - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MSN
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - MSN
Bristol Myers Squibb (BMY) CEO Calls for Fair Global Drug Pricin - GuruFocus
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.17%
0.93%
자본화:
|
볼륨(24시간):